Topic: mitral regurgitation
LivaNova plans to restructure its heart valve operations, and will drop its investigational Caisson transcatheter mitral valve replacement altogether.
Just after starting a large trial of its TriClip, Abbott presented new data from a smaller, single-arm analysis showing improvements after 6 months.
Ancora Heart kicked off a clinical study of its device to repair an enlarged left ventricle from the inside, in patients with heart failure.
The latest generation of Abbott’s market-leading MitraClip device for repairing leaky heart valves was approved with newly flexible steering, navigation and positioning capabilities, for more precise placement during the minimally invasive procedure.
In January, Boston Scientific paid $90 million for a portion of Millipede's shares. Now, it's picking up the rest for $325 million.
A clinical trial showed that Abbott’s MitraClip improved survival in patients with leaky heart valves damaged by heart failure.
Polares Medical raised $25 million to begin clinical testing of its transcatheter mitral valve repair/replacement system.
The agreement sees Boston Scientific buy $90 million of Millipede stock and gain the right to acquire the rest of the business for up to $450 million.
The takeover gives Edwards control of a technology to repair the hearts of patients with the degenerative form of mitral valve disease.
Medtronic has posted a look at data on the first 50 patients treated with its transcatheter mitral valve replacement (TMVR) system.